Loading...
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol (LDL‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately control...
Saved in:
Published in: | J Am Heart Assoc |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
John Wiley and Sons Inc.
2016
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079013/ https://ncbi.nlm.nih.gov/pubmed/27625344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003421 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|